Brief: Zealand Pharma, OTR Therapeutics Enter Strategic Collaboration
Dec 11 (Reuters) - Zealand Pharma A/S ZELA.CO: ZEALAND PHARMA AND OTR THERAPEUTICS ENTER MULTI-PROGRAM STRATEGIC COLLABORATION AND LICENSE AGREEMENT TO DEVELOP NOVEL THERAPEUTICS FOR METABOLIC DISEASES OTR THERAPEUTICS TO RECEIVE INITIAL USD 20 MILLION OTR THERAPEUTICS ELIGIBLE FOR TOTAL CONSIDERATION UP TO USD 2.5 BILLION Source text: ID:nGNE1tTWVV Further company coverage: ZELA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)